The review identifies mRNA vaccines as one of the RNA therapeutic modalities being assessed for multiple myeloma modulation.
First-pass extracted concept
mRNA vaccines
Candidate: concept label7 source documents19 linked claims
Live refresh every 5sNext refresh in 5s
Extracted Explainers
What the tool is doing
The abstract identifies mRNA vaccines as a cutting-edge platform for delivering vaccine antigens to the immune system.
The review describes mRNA or DNA vaccines as delivering genetic instructions to host cells so those cells produce and expose spike protein. This is presented as a non-traditional vaccine modality used to induce neutralizing antibodies.
What problem it solves
It is presented as part of the search for innovative strategies for an incurable, heterogeneous disease with resistance and toxicity challenges.
They are presented as part of biotechnology strategies intended to improve vaccine immunogenicity, safety, and accessibility.
The stated purpose is pandemic control by inducing neutralizing antibodies against spike proteins.
What it does not solve
Evidence Snippets
modalities including mRNA vaccines
Recent advances in nucleic acid-based platforms, particularly mRNA and DNA vaccines, have accelerated clinical translation.
This review explores the cutting-edge platforms-including mRNA, DNA, virus-like particles, viral and bacterial vectors, and bacteriophage-based vaccines
Messenger RNA (mRNA) vaccines have revolutionized the field of vaccinology, offering rapid design flexibility, scalable manufacturing, and strong immunogenicity.
The COVID-19 pandemic spurred unprecedented advances in vaccine technology - particularly mRNA vaccines - reviving interest in novel platforms for bacterial diseases.
These vaccines do not act like traditional protein-based vaccines, as they deliver the message in the form of mRNA or DNA to host cells that then produce and expose the Spike protein on the membrane
The review title is 'mRNA vaccines — a new era in vaccinology'.
Supporting Sources
Linked Claims
Recent advances in mRNA and DNA vaccine platforms have accelerated clinical translation of therapeutic cancer vaccines.
The review assesses RNA-based therapeutic modalities for multiple myeloma including mRNA vaccines, siRNAs, ASOs, and miRNA mimics or inhibitors using preclinical and clinical evidence.
Quoted textsource-backed
In this review, we assess cutting-edge RNA-based therapeutics for MM modulation, drawing on preclinical and clinical evidence on modalities including mRNA vaccines, small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and microRNA (miRNA) mimics/inhibitors.
The review concludes that RNA technologies have transformative potential in refractory multiple myeloma to achieve durable remissions, overcome resistance, reduce costs, and enable more personalized and safer treatments.
Quoted textsource-backed
By integrating these insights, we underscore RNA technologies' transformative potential to achieve durable remissions, overcome resistance, and reduce costs-paving the way for personalized, safer treatments in refractory MM.
mRNA vaccines offer rapid design flexibility, scalable manufacturing, and strong immunogenicity.
Critical challenges for mRNA vaccine development persist in vaccine stability, delivery efficiency, large-scale manufacturing, and global accessibility.
mRNA vaccine candidates against tuberculosis had entered clinical trials by the time of this review.
Quoted textsource-backed
We highlight recent progress such as mRNA vaccine candidates against TB entering clinical trials
The success of COVID-19 mRNA vaccines accelerated research into novel delivery platforms and expanded therapeutic applications beyond infectious diseases to cancer immunotherapy and immune-mediated disorders.
mRNA vaccines offer the opportunity to induce both robust antibody and T-cell responses needed for intracellular infections such as tuberculosis.
Quoted textsource-backed
We discuss the unique opportunities of mRNA vaccines to induce both robust antibody and T-cell responses required for intracellular infections like TB
Future mRNA vaccine development and clinical translation may be accelerated by integrating artificial intelligence, nanotechnology, and systems immunology.
Antigen discovery and delivery, including lipid nanoparticle delivery, remain challenges for mRNA vaccines against bacterial pathogens.
Quoted textsource-backed
as well as the challenges of antigen discovery and delivery (e.g. lipid nanoparticles)
The review covers mRNA, DNA, virus-like particle, viral vector, bacterial vector, and bacteriophage-based vaccine platforms as innovations redefining antigen delivery to the immune system.
This article reviews next-generation bacterial vaccine strategies including mRNA, DNA, self-amplifying RNA, viral vector vaccines, and nanoparticle technologies.
Quoted textsource-backed
Here we review next-generation vaccine strategies, focusing on nucleic acid-based platforms such as mRNA, DNA, and self-amplifying RNA (saRNA), as well as viral vector vaccines. We also examine nanoparticle technologies that serve as delivery systems or adjuvant platforms across these approaches.
mRNA vaccine design includes mRNA engineering strategies and delivery innovations such as lipid nanoparticles, polymeric nanoparticles, virus-like particles, and needle-free administration technologies.
Biotechnology is enabling the design of safer, more efficient, and more adaptable vaccines to address existing and emerging infectious diseases.
The review states that adverse effects associated with genetically based vaccines mainly affect the circulatory and cardiovascular system.
mRNA or DNA vaccines deliver genetic instructions to host cells, which then produce and expose spike protein on the membrane, and spike can also be shed in soluble form.
SARS-CoV-2 uses spike protein to infect target cells that express ACE2 on the membrane.
The review frames spike protein from SARS-CoV-2 or from mRNA-based vaccines as interfering with the ACE2-governed Renin-Angiotensin-System and altering cardiovascular homeostasis.
The review covers mRNA vaccine platforms spanning delivery systems, nucleoside modification strategies, and both non-replicating and self-amplifying RNA formats.